Moleculin Biotech, Inc. (0K2H)

Profile

https://moleculin.com

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections. Its current pipeline centers on Annamycin, an anthracycline-based candidate being evaluated in combination regimens for relapsed or refractory acute myeloid leukemia and other tumor indications, including soft tissue sarcoma lung metastases. The company also advances programs aimed at difficult viral diseases, reflecting a broader approach to unmet medical needs in oncology and virology. Moleculin Biotech works as a specialty drug developer, with research and clinical operations designed to move product candidates through late-stage development and regulatory review. Based in Houston, Texas, the company occupies a niche position in the biopharmaceutical market, where it contributes experimental treatment options for conditions with limited current therapies.